keyword
MENU ▼
Read by QxMD icon Read
search

GEICO

keyword
https://www.readbyqxmd.com/read/27789470/topotecan-plus-carboplatin-versus-standard-therapy-with-paclitaxel-plus-carboplatin-pc-or-gemcitabine-plus-carboplatin-gc-or-pegylated-liposomal-doxorubicin-plus-carboplatin-pldc-a-randomized-phase-iii-trial-of-the-noggo-ago-study-group-ago-austria-and-geico
#1
J Sehouli, R Chekerov, A Reinthaller, R Richter, A Gonzalez-Martin, P Harter, H Woopen, E Petru, L C Hanker, E Keil, P Wimberger, P Klare, C Kurzeder, F Hilpert, A K Belau, A Zeimet, I Bover-Barcelo, U Canzler, S Mahner, W Meier
BACKGROUND: Randomized, phase III trial to evaluate safety and efficacy of topotecan and carboplatin (TC) compared with standard platinum-based combinations in platinum-sensitive recurrent ovarian cancer (ROC). PATIENTS AND METHODS: Patients were randomly assigned in a 1:1 ratio to the experimental TC arm (topotecan 0.75 mg/m(2)/ days 1-3 and carboplatin AUC 5 on day 3 every 3 weeks) or to one of the standard regimes [(PC) paclitaxel plus carboplatin; (GC) gemcitabine plus carboplatin; (PLDC) pegylated liposomal doxorubicin and carboplatin] which could be chosen by individual preference but before randomization...
October 26, 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/26304156/randomized-study-of-sequential-cisplatin-topotecan-carboplatin-paclitaxel-versus-carboplatin-paclitaxel-effects-on-quality-of-life
#2
RANDOMIZED CONTROLLED TRIAL
Lori Brotto, Michael Brundage, Paul Hoskins, Ignace Vergote, Andres Cervantes, Herraez A Casado, A Poveda, Elizabeth Eisenhauer, Dongsheng Tu
BACKGROUND: A recent phase III trial compared the efficacy of cisplatin-topotecan (a topoisomerase I inhibitor) followed by carboplatin-paclitaxel (Arm 1) versus paclitaxel-carboplatin (Arm 2) in women with newly diagnosed stage IIB or greater ovarian cancer. There was a significantly lower response rate in the experimental arm compared to standard treatment, and less likelihood of normalized CA125 within the first 3 months. At 43 months follow-up, there were no significant group differences in progression-free survival...
March 2016: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/25132514/oxidative-damage-in-diabetics-insights-from-a-graduate-study-in-la-reunion-university
#3
Dorothée Girard, Philippe Rondeau, Aurélie Catan, Cynthia Planesse, Pierre Giraud, Emmanuel Bourdon
Due to the growing incidence of diabetes in developed nations, there is a compelling case to be made for teaching graduate students more deeply about mechanisms underlying this disease. Diabetes is associated with enhanced oxidative stress and protein glycation via the covalent binding of glucose molecules. Albumin represents the major plasmatic protein and undergoes enhanced glycoxidative modifications in diabetic condition. La Réunion Island, a French department located in the Indian Ocean exhibit a growing incidence of diabetes...
September 2014: Biochemistry and Molecular Biology Education
https://www.readbyqxmd.com/read/24524383/a-multicenter-randomized-controlled-trial-of-a-nutrition-intervention-program-in-a-multiethnic-adult-population-in-the-corporate-setting-reduces-depression-and-anxiety-and-improves-quality-of-life-the-geico-study
#4
Ulka Agarwal, Suruchi Mishra, Jia Xu, Susan Levin, Joseph Gonzales, Neal D Barnard
PURPOSE: To determine whether a plant-based nutrition program in a multicenter, corporate setting improves depression, anxiety, and productivity. DESIGN: A quasi-experimental study examined the impact of diet on emotional well-being and productivity. SETTING: The study was conducted in 10 corporate sites of a major U.S. insurance company. SUBJECTS: There were 292 participants (79.8% women, 20.2% men), with body mass index ≥25 kg/m(2) and/or previous diagnosis of type 2 diabetes...
March 2015: American Journal of Health Promotion: AJHP
https://www.readbyqxmd.com/read/23942177/nutrient-intake-in-the-geico-multicenter-trial-the-effects-of-a-multicomponent-worksite-intervention
#5
RANDOMIZED CONTROLLED TRIAL
S Mishra, N D Barnard, J Gonzales, J Xu, U Agarwal, S Levin
BACKGROUND/OBJECTIVES: To assess the effects on macro- and micronutrient intake of a nutrition intervention program in corporate settings across the United States. SUBJECTS/METHODS: Two hundred and ninety-two individuals who were overweight or had type 2 diabetes were recruited from 10 sites of a US insurance company. Two hundred and seventy-one participants completed baseline diet recalls, and 183 participants completed dietary recalls at 18 weeks. Sites were randomly assigned to an intervention group (five sites) or to a control group (five sites) for 18 weeks...
October 2013: European Journal of Clinical Nutrition
https://www.readbyqxmd.com/read/23695207/a-multicenter-randomized-controlled-trial-of-a-plant-based-nutrition-program-to-reduce-body-weight-and-cardiovascular-risk-in-the-corporate-setting-the-geico-study
#6
RANDOMIZED CONTROLLED TRIAL
S Mishra, J Xu, U Agarwal, J Gonzales, S Levin, N D Barnard
BACKGROUND/OBJECTIVES: To determine the effects of a low-fat plant-based diet program on anthropometric and biochemical measures in a multicenter corporate setting. SUBJECTS/METHODS: Employees from 10 sites of a major US company with body mass index ≥ 25 kg/m(2) and/or previous diagnosis of type 2 diabetes were randomized to either follow a low-fat vegan diet, with weekly group support and work cafeteria options available, or make no diet changes for 18 weeks...
July 2013: European Journal of Clinical Nutrition
https://www.readbyqxmd.com/read/23478059/abagovomab-as-maintenance-therapy-in-patients-with-epithelial-ovarian-cancer-a-phase-iii-trial-of-the-ago-ovar-cogi-gineco-and-geico-the-mimosa-study
#7
RANDOMIZED CONTROLLED TRIAL
Paul Sabbatini, Philipp Harter, Giovanni Scambia, Jalid Sehouli, Werner Meier, Pauline Wimberger, Klaus H Baumann, Christian Kurzeder, Barbara Schmalfeldt, David Cibula, Mariusz Bidzinski, Antonio Casado, Andrea Martoni, Nicoletta Colombo, Robert W Holloway, Luigi Selvaggi, Andrew Li, Jose del Campo, Karel Cwiertka, Tamas Pinter, Jan B Vermorken, Eric Pujade-Lauraine, Simona Scartoni, Monica Bertolotti, Cecilia Simonelli, Angela Capriati, Carlo Alberto Maggi, Jonathan S Berek, Jacobus Pfisterer
PURPOSE: To determine whether abagovomab maintenance therapy prolongs recurrence-free (RFS) and overall survival (OS) in patients with ovarian cancer in first clinical remission. PATIENTS AND METHODS: Patients with International Federation of Gynecology and Obstetrics stage III to IV ovarian cancer in complete clinical remission after primary surgery and platinum- and taxane-based chemotherapy were randomly assigned at a ratio of 2:1 in a phase III, double-blind, placebo-controlled, multicenter study...
April 20, 2013: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/23468275/geico-spanish-group-for-investigation-on-ovarian-cancer-treatment-guidelines-in-ovarian-cancer-2012
#8
A González Martín, A Redondo, M Jurado, A De Juan, I Romero, I Bover, J M Del Campo, A Cervantes, Y García, J A López-Guerrero, C Mendiola, J Palacios, M J Rubio, A Poveda Velasco
In 2006, under the auspices of The Spanish Research Group for Ovarian Cancer (Spanish initials GEICO), the first "Treatment Guidelines in Ovarian Cancer" were developed and then published in Clinical and Translational Oncology by Poveda Velasco et al. (Clin Transl Oncol 9(5):308-316, 2007). Almost 6 years have elapsed and over this time, we have seen some important developments in the treatment of ovarian cancer. Significant changes were also introduced after the GCIG-sponsored 4th Consensus Conference on Ovarian Cancer by Stuart et al...
July 2013: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/21738038/feasibility-of-a-modified-outpatient-regimen-of-intravenous-intraperitoneal-chemotherapy-in-optimally-debulked-stage-iii-ovarian-cancer-patients-a-geico-study
#9
Ana Oaknin, Desamparado Roda, Antonio González-Martín, Luis Chiva, Jesús García-Donas, Ana de Juan, Andrés Redondo, Sergio Martínez, Yolanda García, Sílvia Catot, Jordi Ponce, J M Del Campo, Andrés Cervantes, Andrés Poveda
OBJECTIVES: The objective of the study was to assess the feasibility, toxicity, and reasons for early discontinuation of a modified outpatient intraperitoneal/intravenous (IP/IV) chemotherapy regimen for the treatment of patients with optimally debulked stage III ovarian cancer. METHODS: Between February 2006 and November 2008, 51 consecutive patients from Institutions of the Spanish Ovarian Cancer Group (GEICO) were treated with a modified outpatient IP chemotherapy regimen...
August 2011: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/20594095/a-multicomponent-intervention-reduces-body-weight-and-cardiovascular-risk-at-a-geico-corporate-site
#10
Hope R Ferdowsian, Neal D Barnard, Valerie J Hoover, Heather I Katcher, Susan M Levin, Amber A Green, Joshua L Cohen
PURPOSE: To determine whether a multicomponent nutrition intervention program at a corporate site reduces body weight and improves other cardiovascular risk factors in overweight individuals. DESIGN: Prospective clinical intervention study. SUBJECTS/SETTING: Employees of the Government Employees Insurance Company (GEICO) (N = 113), aged 21 to 65 years, with a body mass index > or =25 kg/m(2) and/or previous diagnosis of type 2 diabetes...
July 2010: American Journal of Health Promotion: AJHP
https://www.readbyqxmd.com/read/18838886/a-phase-ii-trial-of-fixed-dosed-rate-gemcitabine-in-platinum-resistant-ovarian-cancer-a-geico-grupo-espa%C3%A3-ol-de-investigaci%C3%A3-n-en-c%C3%A3-ncer-de-ovario-trial
#11
Belen Ojeda Gonzalez, Antonio Gonzalez Martin, Isabel Bover Barcelo, Xavier Fabregat i Mayol, Begoña Mellado, María Jesus Rubio Perez, Lorenzo Alonso Carrion, Antonio Casado Herraez, Elisa Calvo Garcia, Cristina Churruca Galaz, Angels Arcusa Lanza, Ana Herrero Ibañez, Encarna Adrover Cebrian, Andres Poveda Velasco
OBJECTIVES: Gemcitabine has well-recognized activity in the treatment of ovarian cancer. Fixed-dose rate (FDR) delivery has been proposed as a more rationale way to administer gemcitabine, to avoid saturation of the enzyme that catalyzes its intracellular transformation into the active metabolites, difluorodeoxycitidine biphosphate, and triphosphate. Our aim was to assess clinical activity of gemcitabine delivered by FDR infusion in patients with platinum resistant ovarian cancer. MATERIALS AND METHODS: Patients with platinum-resistant ovarian cancer received gemcitabine 1000 mg/m(2) over 120 minutes on days 1 and 8 of each cycle...
October 2008: American Journal of Clinical Oncology
https://www.readbyqxmd.com/read/18336404/ten-years-of-optimal-therapy-in-advanced-ovarian-cancer-update-meeting
#12
A Poveda
The International Symposium on Advanced Ovarian Cancer: Optimal Therapy was founded by Dr. Andrés Poveda and Prof. Jan B. Vermorken, and each edition has been directed by them. The 6th edition was held on March 2, 2007. This symposium is organized every other year by GEICO (Grupo Español de Investigación de Cáncer de Ovario/Spanish Ovarian Cancer Research Group), under the auspices of the Spanish Society of Medical Oncology (SEOM), the Gynecologic Cancer Intergroup (GCIG), and the European Society of Medical Oncology (ESMO) Educational Committee for its Medical Oncology Recertification Approval (ESMO/MORA) Program...
March 2008: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/17525041/treatment-guidelines-in-ovarian-cancer
#13
A Poveda Velasco, A Casado Herráez, A Cervantes Ruipérez, D Gallardo Rincón, E García García, A González Martín, G López García, C Mendiola Fernández, B Ojeda González
National and international specialists have met with the aim of writing down the guidelines for the treatment of epithelial ovarian cancer (in the Spanish Castilian language). These guidelines are based on the International Consensus that was published in English in the Annals of Oncology in 2005. This condition is the leading cause of death from gynaecological cancer in western countries. Its low rate of survival, barely 30% at 5 years, is above all due to late diagnosis and inappropriate surgery, so emphasis is put on these aspects...
May 2007: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/16343239/treatment-of-recurrent-disease-randomized-trials-of-monotherapy-versus-combination-chemotherapy
#14
REVIEW
A González-Martín
Recurrent ovarian carcinoma is normally an incurable disease situation in which chemotherapy is the usual treatment for palliation. The probability of response to chemotherapy depends on the time from last chemotherapy and the previous response observed. The issue of combination chemotherapy versus monotherapy is a clinically relevant dilemma for medical and gynecologic oncologist involved in the treatment of recurrent patients. In those patients with platinum-resistant relapse, combination chemotherapy has been associated with higher toxicity without a clear clinical benefit in randomized clinical trials...
November 2005: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/16239238/2004-consensus-statements-on-the-management-of-ovarian-cancer-final-document-of-the-3rd-international-gynecologic-cancer-intergroup-ovarian-cancer-consensus-conference-gcig-occc-2004
#15
A du Bois, M Quinn, T Thigpen, J Vermorken, E Avall-Lundqvist, M Bookman, D Bowtell, M Brady, A Casado, A Cervantes, E Eisenhauer, M Friedlaender, K Fujiwara, S Grenman, J P Guastalla, P Harper, T Hogberg, S Kaye, H Kitchener, G Kristensen, R Mannel, W Meier, B Miller, J P Neijt, A Oza, R Ozols, M Parmar, S Pecorelli, J Pfisterer, A Poveda, D Provencher, E Pujade-Lauraine, M Randall, J Rochon, G Rustin, S Sagae, F Stehman, G Stuart, E Trimble, P Vasey, I Vergote, R Verheijen, U Wagner
No abstract text is available yet for this article.
2005: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/16239236/the-gynecologic-cancer-intergroup-gcig-history-and-current-status
#16
REVIEW
J B Vermorken, E Avall-Lundqvist, J Pfisterer, M Bacon, , , , , , , , , , , , , et al.
No abstract text is available yet for this article.
2005: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/16239235/3rd-international-ovarian-cancer-consensus-conference-outstanding-issues-for-future-consideration
#17
G Stuart, E Avall-Lundqvist, A du Bois, M Bookman, D Bowtell, M Brady, A Casado, A Cervantes, E Eisenhauer, M Friedlaender, K Fujiwara, S Grenman, J P Guastalla, P Harper, T Hogberg, S Kaye, H Kitchener, G Kristensen, R Mannel, W Meier, B Miller, A Oza, R Ozols, M Parmar, J Pfisterer, A Poveda, D Provencher, E Pujade-Lauraine, M Quinn, M Randall, J Rochon, G Rustin, S Sagae, F Stehman, E Trimble, T Thigpen, P Vasey, I Vergote, R Verheijen, J Vermorken, U Wagner, , , , , , , , , , , , et al.
No abstract text is available yet for this article.
2005: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/16239234/integration-of-new-or-experimental-treatment-options-and-new-approaches-to-clinical-trials
#18
M Quinn, J Pfisterer, E Avall-Lundqvist, M Bookman, D Bowtell, A Casado, A Cervantes, S Grenman, P Harper, A Oza, S Pecorelli, E Pujade-Lauraine, E Trimble, P Vasey, U Wagner, , , , , , , , , , , et al.
No abstract text is available yet for this article.
2005: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/16239232/clinical-trials-in-ovarian-carcinoma-requirements-for-standard-approaches-and-regimens
#19
T Thigpen, G Stuart, A du Bois, M Friedlander, K Fujiwara, J P Guastalla, S Kaye, H Kitchener, G Kristensen, R Mannel, W Meier, B Miller, A Poveda, D Provencher, F Stehman, I Vergote
No abstract text is available yet for this article.
2005: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/15817604/randomized-phase-ii-trial-of-carboplatin-versus-paclitaxel-and-carboplatin-in-platinum-sensitive-recurrent-advanced-ovarian-carcinoma-a-geico-grupo-espanol-de-investigacion-en-cancer-de-ovario-study
#20
RANDOMIZED CONTROLLED TRIAL
A J González-Martín, E Calvo, I Bover, M J Rubio, A Arcusa, A Casado, B Ojeda, C Balañá, E Martínez, A Herrero, B Pardo, E Adrover, J Rifá, M J Godes, A Moyano, A Cervantes
BACKGROUND: The aim of this study was to determine whether the response rate for the paclitaxel-carboplatin combination is superior to carboplatin alone in the treatment of patients with platinum-sensitive recurrent ovarian carcinoma. PATIENTS AND METHODS: Patients with recurrent ovarian carcinoma, 6 months after treatment with a platinum-based regimen and with no more than two previous chemotherapy lines, were randomized to receive carboplatin area under the curve (AUC) 5 (arm A) or paclitaxel 175 mg/m(2) + carboplatin AUC 5 (arm B)...
May 2005: Annals of Oncology: Official Journal of the European Society for Medical Oncology
keyword
keyword
22867
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"